Ascelia Pharma (ACE) investor relations material

Executive summary

• Orviglance, a manganese-based MRI contrast agent for patients with severe renal impairment, had its NDA accepted by the FDA with a PDUFA date set for July 3, 2026, targeting a USD 800 million global market.

• Orviglance completed nine clinical studies, including a pivotal Phase 3 trial meeting its primary endpoint with high statistical significance, and holds orphan drug designation.

• Commercialization strategy focuses on partnerships, with multiple discussions ongoing and launch readiness preparations underway.

• Oncoral, an oral irinotecan chemotherapy, is advancing to Phase 2 for gastric cancer, supported by a clinical collaboration.

• Key management changes include a new CFO, a new patent application for Orviglance, and the planned departure of the Deputy CEO.

Financial highlights

• Q4 2025 operating loss was SEK 16 million, with a full-year operating loss of SEK 74.4 million, reflecting lower R&D costs after NDA submission.

• Net loss for Q4 2025 was SEK 15.9 million; full-year net loss was SEK 76.3 million.

• Liquid assets at year-end 2025 were SEK 49.9 million, with a SEK 30 million directed share issue in September 2025.

• Cash runway extends into Q4 2026, beyond the expected FDA approval date.

• No net sales reported; other operating income was minimal and related to exchange rate gains.

Outlook and guidance

• FDA decision on Orviglance expected by July 2026, with launch and partnership preparations progressing.

• Confident in securing a partner before commercialization; timeline not expected to jeopardize launch.

• 2026 expected to be transformative, with anticipated FDA approval and commercial launch through partners.